About
Company Profile
Management Team
Honors Course
Vision & Mission
Chengdu Biostar
Synthetic Biology
R&D
Pipeline
Clinical Recruitment
Partnering
Cooperative Partners
Business development
IR
Product
Utidelone
Medical consultation and Drug Safety Hotline
News
Contact
Career
Contact
CN
菜单
search
Index
About
Company Profile
Management Team
Honors Course
Vision & Mission
Chengdu Biostar
Synthetic Biology
R&D
Pipeline
Clinical Recruitment
Partnering
Cooperative Partners
Business development
IR
Product
Utidelone
Medical consultation and Drug Safety Hotline
Contact
Career
Contact
news
Company News
all
all
2021
2020
2019
2024-11-14
Biostar to collaborate with Baheal Medical to accelerate the commercialization process of Utidelone
2024-09-03
Biostar Announces Completion of Patient Recruitment for US Phase 1 Clinical Study of Utidelone Capsule
2024-07-05
Biostar Pharma Announces FDA Clearance of the IND Application for a Phase 2 Study of Utidelone Injection (UTD1) in HER2- Breast Cancer Brain Metastasis
2024-03-28
73% CNS ORR! FDA Granted ODD to Utidelone Injectable (UTD1) from Biostar Pharma for the Treatment of Breast Cancer Brain Metastasis
2024-03-21
100% CBR! FDA Granted ODD to Biostar Pharma's Utidelone Capsule (UTD2) for the Treatment of Gastric Cancer
2023-06-16
FDA Approved Utidelone Injectable (UTD1) Phase 2/3 Multi-National Clinical Trial for Non-Small Cell Lung Cancer
2023-06-12
Biostar Pharma Announces First Patient Enrolled for Phase 1 Study of Utidelone Capsule (UTD2)—The World's First Oral Epothilone Anti-Cancer Drug